Navigation Links
Study to Investigate Gene's Effect on Bone Loss in Breast Cancer Patients

Women with estrogen-responsive breast cancer are often prescribed a drug that reduces their estrogen levels. But because estrogen is important to bone health, there is widespread concern about how the estrogen-reducing drugs - called aromatase inhibitors - affect bones.

A study at Washington University School of Medicine in St. Louis will investigate bone loss in women taking aromatase inhibitors, and researchers are calling for interested women to volunteer.

Aromatase is an enzyme that transforms testosterone and other androgens into estrogen. This process represents the major, if not only, source of estrogen in postmenopausal women. So giving women aromatase inhibitors can result in nearly complete shutdown of estrogen production, which can have unwanted side effects.

"There are reports of an increased incidence of fractures in women on aromatase inhibitors," says Reina Armamento-Villareal, M.D., assistant professor of medicine in the Division of Bone and Mineral Diseases and a Washington University bone specialist at Barnes-Jewish Hospital. "But interestingly, studies show that women respond differently to these drugs, possibly because of variations in the gene that produces the aromatase enzyme."

This gene is CYP19. Scientists have identified several variations of CYP19 that can result in either increased or decreased aromatase activity. This in turn influences how aromatase inhibitors affect estrogen levels. The Washington University study will analyze the sequence of the CYP19 gene in volunteers to see which variation they possess.

"Our hypothesis is that the use of aromatase inhibitors can be associated with significant bone loss, and the degree of bone loss will be related to the variations of the CYP19 gene," Villareal says.

The data the researchers collect from the study will aid in establishing the appropriate approach to maintaining bone health in women who are given aromatase inhib itors. This study is an example of how physicians hope to use a patient's genetic code to create personalized treatment.

"As more breast cancer patients use these drugs, more may be expected to experience osteoporotic (porous bone) complications," Villareal says. "We are attempting to address this issue to identify those that would need early intervention to prevent bone loss with aromatase inhibitor therapy."

Postmenopausal women with breast cancer are eligible to participate. The researchers will compare bone loss in women taking aromatase inhibitors to those not using these drugs, so both groups are wanted for the study. The study will not require participants to alter their cancer treatment.

Participants will receive free bone density scans and will be tested for blood markers that indicate bone turnover. Each volunteer will be genotyped for CYP19 variants to investigate any link between genetic profile and bone loss.


'"/>




Related medicine news :

1. Tomato Sauce reduces Cancer Risk- Study
2. Study on obesity and heart failure
3. National Lung Study in the process
4. Study casts doubt on keyboard ills
5. Study reveals how stress can make you sick
6. Study reveals how stress can make you sick
7. Study supports vegetable diet
8. Study to look at early surgery to treat epilepsy
9. Its Never Too Late to Stop Smoking,Study Finds
10. New Technique to Study Infants Brain.
11. Groundbreaking Study Gives Hope For Patients With Kidney Cancer
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/22/2017)... Burlingame, CA (PRWEB) , ... February 22, 2017 ... ... of American adults with chronic conditions reported skipping doses or not filling a ... were uninsured or under-insured, rates of cost-related problems getting medications were 30-60%*. ...
(Date:2/22/2017)... Singapore (PRWEB) , ... February 22, 2017 , ... Using ... medical leads utilizing a simple online checklist. Over a period of just 24 months, ... the assistance of an online checklist called T.A.D. , “The internet is not getting ...
(Date:2/22/2017)... ... February 22, 2017 , ... Bellus ... the latest innovation in the delivery of Platelet Rich Plasma (PRP). PRP systems ... pain management, to accelerate tissue synthesis and provide a faster and more efficient ...
(Date:2/22/2017)... ... 22, 2017 , ... Super-Sod will attend the Athens Home Show with a ... A shift from Super-Sod’s simple Athens Home Show booth of 2016, this year’s exhibit ... plant manager Chris Roquemore constructed furniture from recycled pallet wood at the Super-Sod farm ...
(Date:2/22/2017)... ... February 22, 2017 , ... In today’s ... different solutions on the market, it is easy to start feeling frustrated and ... offers a complimentary security consultation. , Home Security Hardware Choices, There are ...
Breaking Medicine News(10 mins):
(Date:2/22/2017)... , Feb 22, 2017 Research and Markets ... Analysis & Trends - Industry Forecast to 2025" report to their ... The Global Clot ... 5.2% over the next decade to reach approximately $2.1 billion by 2025. ... forecasts for all the given segments on global as well as regional ...
(Date:2/22/2017)... Research and Markets has announced the addition of the ... Trend Indicator):Analysis By Region, By Country (2016-21)" report to their ... Global ... CAGR of 5.33% during 2016-2021 The strong growth is ... demand of digital thermometer. Apart from that, the downfall in the ...
(Date:2/22/2017)... DUBLIN , Feb. 22, 2017  Allergan ... is proud to be a Gold sponsor of ... National Educating America Tour." This tour commemorates AFA,s15 ... availability of services and programs. The tour will ... free memory screenings and displays of the AFA ...
Breaking Medicine Technology: